// App-Quantinova.ai

3870 : SLFN11 is a biomarker of sensitivity to PARP inhibition and chemotherapy in small cell lung cancer (SCLC)

Researchers

Presenter

  • C. Allison Stewart

Principal Investigators

  • Pan Tong

  • Robert Cardnell

  • Triparna Sen

  • Fatemah Mina Masrorpour

  • Youhong Fan

  • Jing Wang

  • Lauren Averett Byers

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Small cell lung cancer

  • Prostate cancer

  • Ewing's sarcoma

  • Lung Cancer

  • Sarcoma

  • Solid malignancies

Biomarkers

  • Poly(ADP-Ribose) Polymerase 1

  • ETS transcription factor ERG

  • EWS RNA Binding Protein 1

Drug/Treatment

  • Irinotecan

  • Cisplatin

  • Topotecan Hydrochloride

  • Olaparib

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved